These data led to the testing of inhibitors of DGAT1 in human clinical trials for the treatment of obesity and metabolic syndrome22, since the drugs prevent both TAG synthesis and LD formation23. This evidence concerns the gene DGAT1 and obesity due to melanocortin 4 receptor deficiency.